Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
• Atherothrombosis, the major cause of acute coronary syndromes, remains the world’s leading cause of morbidity and mortality. Platelets are central to the process of atherothrombosis and, therefore, antiplatelet therapies have been widely advocated in managing this disorder.
• Low-dose aspirin (acetylsalicylic acid) is commonly prescribed as an antiplatelet therapy for secondary prevention of serious ischemic events. However, recent reports suggest that not all patients respond to low-dose aspirin to the same degree. Conservative estimates of aspirin nonresponsiveness (also known as ‘aspirin resistance’) range from 5 to 25%, depending on the testing platform and clinical status of the tested patient population.
• The prevalence of aspirin resistance suggests a need for a test to monitor aspirin response in the individual patient. Such a test would allow for individualized treatment rather than treatment of the disease on a population basis.
• Historical methods to assess the effect of aspirin on platelet function involve ex vivo platelet aggregation techniques that are not conducive to mass screening of individuals.
• Aspirin exerts its antiplatelet effect through inhibition of the platelet cyclooxygenase (COX) pathway and subsequent reduction in thromboxane A2 (TxA2) production. Assessment of the adequacy of COX-1 pathway inhibition by aspirin can be performed by measuring levels of 11-dehydrothromboxane B2 (11dhTxB2), a stable metabolite of TxA2.
• AspirinWorks® is an FDA cleared competitive immunoassay in microplate format that measures levels of 11dhTxB2 in urine specimens. This test may be used by physicians to monitor aspirin effect and assist in optimizing antiplatelet therapy in individual patients.
- Lopez AD, Murray CCJL. The global burden of disease, 1990–2020. Nat Med 1998 Nov; 4(ll): 1241–3 CrossRef
- Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002 Nov; 8(11): 1227–34 CrossRef
- Craven LL. Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Miss Valley Med J 1953 Jan; 75(1): 38–44
- Sanderson S, Emery J, Baglin T, et al. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 2005 Mar 1; 142(5): 370–80
- Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006 Feb 18; 367(9510): 606–17 CrossRef
- Born GV, Cross MJ. The aggregation of blood platelets. J Physiol 1963 Aug; 168: 178–95
- Faraday N, Becker DM, Yanek LR, et al. Relation between atherosclerosis risk factors and aspirin resistance in primary prevention population. Am J Cardiol 2006 Sep 15; 98(6): 774–9 CrossRef
- Markuszewski L, Rosiak M, Golanski J, et al. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin? Basic Clin Pharm Tox 2006 May; 98(5): 503–9 CrossRef
- Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002 Apr 9; 105(14): 1650–5 CrossRef
- Aspirin Works®
Molecular Diagnosis & Therapy
Volume 12, Issue 1 , pp 51-54
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors